Akums Drugs & Pharmaceuticals Ltd (AKUMS)
₹687.30
Mkt cap
₹10,892 Cr
P/E ratio
40.60
P/B
3.26
Div yield
0.14%
ROE
8.45%
ROCE
14.90%
EPS (TTM)
₹16.93
Book value
₹211
52W range
414–702
Sector
Healthcare
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. [1]
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−2.09% from high₹687
₹414+65.99% from low₹702
Current
₹687.30
Prev close
₹686.00
Day
+0.19%
Price performance
1D
+0.19%
1W
+1.59%
1M
+12.79%
3M
+33.64%
6M
+63.08%
1Y
+22.69%
YTD
+52.11%
Financials
FRevenue, profit & margin
P/E ratio
40.6×
AKUMS is 16% above the sector median of 34.9×
AKUMS40.6×
Sector median34.9×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | |
| Expenses | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | |
| OPM % | -13% | 13% | 9% | 0% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | |
| Other Income | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | |
| Profit before tax | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | |
| Tax % | 18% | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | |
| Net Profit | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | |
| EPS in Rs | -13.16 | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202675.26%Promoter
Promoters75.26%
FIIs1.38%0.24
DIIs14.36%0.05
Public6.29%0.16
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,951.50 | 37.68 | 4,68,230 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,273.00 | 73.61 | 1,93,075 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹5,017.80 | 77.49 | 1,69,825 | 0.76% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,438.00 | 30.52 | 1,16,168 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Zydus Lifesci. | ₹1,156.90 | 21.27 | 1,15,401 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,493.00 | 20.05 | 1,13,988 | 0.72% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,543.10 | 52.29 | 1,05,054 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.50% |
| Akums Drugs | ₹692.10 | 40.55 | 10,892 | 0.14% | 81 | −39.44% | 1,158 | +9.69% | 14.94% |
| Median: 156 Co. | ₹434.68 | 34.87 | 2,006 | 0.08% | 12 | +22.43% | 177 | +16.46% | 15.19% |
Filings
DAnnual reports2
Concall transcripts22
Credit ratings6
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 11 JulShareholder Meeting / Postal Ballot-Outcome of AGM 10 Jul - Akums held its 22nd AGM on July 10, 2026; shareholders considered financials, dividend, director reappointment and remuneration revisions.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Jul - Akums filed Regulation 74(5) compliance certificate for quarter ended 30 June 2026.Update On Penalty Imposed By The Deputy Commissioner Of State Tax, Gujarat, On Maxcure Nutravedics Limited, Wholly Owned Subsidiary Of The Company 4 Jul - Gujarat appellate authority set aside ₹3.59 crore penalty on subsidiary Maxcure Nutravedics.Closure of Trading Window 25 Jun - Trading window closed1 July 2026 until 48 hours after Q1 FY27 results.